Expression of vascular endothelial growth factor receptor-1 and -2 in normal and diseased canine eyes

Veterinary Ophthalmology

Volumn 15, Issue 4, 2012, Pages 223-230

  Binder, Daniel R ^a   Herring, Ian P ^a   Zimmerman, Kurt L ^a   Phillip Pickett, J ^a   Huckle, William R ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

Canine; Glaucoma; Immunohistochemistry; Neovascularization; Pre iridal fibrovascular membrane; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; EYE; EYE TUMOR; GENETICS; GLAUCOMA; METABOLISM;

ANIMALS; DOG DISEASES; DOGS; EYE; EYE NEOPLASMS; GLAUCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

CANIS FAMILIARIS;

EID: 84863434477     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2011.00973.x     Document Type: Article

References (62)

1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 1989; 161: 851-858.
2. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 7311-7315.
3. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
4. Ferrara N, Bunting S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Current Opinion in Nephrology and Hypertension 1996; 5: 35-44.
5. Hiscock N, Fischer CP, Pilegaard H et al. Vascular endothelial growth factor mRNA expression and arteriovenous balance in response to prolonged, submaximal exercise in humans. American Journal of Physiology. Heart and Circulatory Physiology 2003; 285: H1759-H1763.
6. Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. Journal of Clinical Investigation 1989; 84: 1470-1478.
7. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
8. Bottomley MJ, Webb NJ, Watson CJ et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clinical and Experimental Immunology 2000; 119: 182-188.
9. Kuroki M, Voest EE, Amano S et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. Journal of Clinical Investigation 1996; 98: 1667-1675.
10. Pertovaara L, Kaipainen A, Mustonen T et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. The Journal of Biological Chemistry 1994; 269: 6271-6274.
11. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. The Journal of Biological Chemistry 1996; 271: 28220-28228.
12. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
13. Stein I, Neeman M, Shweiki D et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Molecular and Cellular Biology 1995; 15: 5363-5368.
14. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004; 25: 581-611.
15. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry 2008; 73: 751-762.
16. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 10705-10709.
17. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Current Opinion in Ophthalmology 2007; 18: 502-508.
18. Esson D, Armour M, Mundy P et al. The histopathological and immunohistochemical characteristics of pigmentary and cystic glaucoma in the Golden Retriever. Veterinary Ophthalmology 2009; 12: 361-368.
19. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmologica Scandinavica 2004; 82: 557-563.
20. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Investigative Ophthalmology and Visual Science 2000; 41: 2514-2522.
21. Stitt AW, Simpson DA, Boocock C et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. The Journal of Pathology 1998; 186: 306-312.
22. Witmer AN, Blaauwgeers HG, Weich HA et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Investigative Ophthalmology and Visual Science 2002; 43: 849-857.
23. Zarfoss MK, Breaux CB, Whiteley HE et al. Canine pre-iridal fibrovascular membranes: morphologic and immunohistochemical investigations. Veterinary Ophthalmology 2010; 13: 4-13.
24. Sandberg CS, Herring IP, Huckle WR et al. (eds). Aqueous humor vascular endothelial growth factor in dogs with intraocular disease. 40th Annual Conference of the American College of Veterinary Ophthalmologists; 2009 Nov. 4. Chicago, IL, 2009.
25. Ambati BK, Nozaki M, Singh N et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993-997.
26. Cursiefen C, Chen L, Saint-Geniez M et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 11405-11410.
27. Shui YB, Wang X, Hu JS et al. Vascular endothelial growth factor expression and signaling in the lens. Investigative Ophthalmology and Visual Science 2003; 44: 3911-3919.
28. Murata M, Kador PF, Sato S. Vascular endothelial growth factor (VEGF) enhances the expression of receptors and activates mitogen-activated protein (MAP) kinase of dog retinal capillary endothelial cells. Journal of Ocular Pharmacology and Therapeutics 2000; 16: 383-391.
29. Saint-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS ONE 2008; 3: e3554.
30. Yonemaru K, Sakai H, Murakami M et al. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. Veterinary Pathology 2006; 43: 971-980.
31. Uchida N, Nagai K, Sakurada Y et al. Distribution of VEGF and flt-1 in the normal dog tissues. Journal of Veterinary Medical Science 2008; 70: 1273-1276.
32. Jais A, Klein D, Wolfesberger B et al. Gene expression profile of vascular endothelial growth factor (VEGF) and its receptors in various cell types of the canine lymph node using laser capture microdissection (LCM). Veterinary Immunology and Immunopathology 2011; 140: 207-214.
33. Kim I, Ryan AM, Rohan R et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Investigative Ophthalmology and Visual Science 1999; 40: 2115-2121.
34. Gilbert RE, Vranes D, Berka JL et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Laboratory Investigation 1998; 78: 1017-1027.
35. Mitchell CA, Risau W, Drexler HC. Regression of vessels in the tunica vasculosa lentis is initiated by coordinated endothelial apoptosis: a role for vascular endothelial growth factor as a survival factor for endothelium. Developmental Dynamics 1998; 213: 322-333.
36. Potts JD, Harocopos GJ, Beebe DC. Identification of receptor tyrosine kinases in the embryonic chicken lens. Current Eye Research 1993; 12: 759-763.
37. Deeg CA, Altmann F, Hauck SM et al. Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood-retinal barrier. Proteomics 2007; 7: 1540-1548.
38. Witmer AN, Dai J, Weich HA et al. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. Journal of Histochemistry and Cytochemistry 2002; 50: 767-777.
39. Blaauwgeers HG, Holtkamp GM, Rutten H et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. American Journal of Pathology 1999; 155: 421-428.
40. Abrams KL, Stabila PF, Kauper K et al. Vascular endothelial growth factor in diabetic and nondiabetic canine cataract patients. Veterinary Ophthalmology 2011; 14: 93-99.
41. Harper JY, Samuelson DA, Reep RL. Corneal vascularization in the Florida manatee (Trichechus manatus latirostris) and three-dimensional reconstruction of vessels. Veterinary Ophthalmology [Evaluation Studies] 2005; 8: 89-99.
42. Peiffer RL Jr, Wilcock BP, Yin H. The pathogenesis and significance of pre-iridal fibrovascular membrane in domestic animals. Veterinary Pathology 1990; 27: 41-45.
43. Deehr AJ, Dubielzig RR. A histopathological study of iridociliary cysts and glaucoma in Golden Retrievers. Veterinary Ophthalmology 1998; 1: 153-158.
44. Moore DL, McLellan GJ, Dubielzig RR. A study of the morphology of canine eyes enucleated or eviscerated due to complications following phacoemulsification. Veterinary Ophthalmology 2003; 6: 219-226.
45. Spiess BM, Bolliger JO, Guscetti F et al. Multiple ciliary body cysts and secondary glaucoma in the Great Dane: a report of nine cases. Veterinary Ophthalmology 1998; 1: 41-45.
46. Wakabayashi T, Oshima Y, Sakaguchi H et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571-1580, 1580 e1571-1573.
47. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Current Opinion in Ophthalmology 2010; 21: 112-117.
48. Wolf A, von Jagow B, Ulbig M et al. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica 2011; 226: 51-56.
49. Lutty GA, McLeod DS, Bhutto I et al. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Investigative Ophthalmology and Visual Science 2011; 52: 4039-4047.
50. Gelatt KN. Veterinary Ophthalmology, 4th edn. Blackwell Pub., Ames, IA, 2007.
51. Boyd SR, Tan D, Bunce C et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. British Journal of Ophthalmology 2002; 86: 448-452.
52. Boyd SR, Tan DS, de Souza L et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. British Journal of Ophthalmology 2002; 86: 440-447.
53. Missotten GS, Notting IC, Schlingemann RO et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Archives of Ophthalmology 2006; 124: 1428-1434.
54. Sahin A, Kiratli H, Soylemezoglu F et al. Expression of vascular endothelial growth factor-A, matrix metalloproteinase-9, and extravascular matrix patterns and their correlations with clinicopathologic parameters in posterior uveal melanomas. Japanese Journal of Ophthalmology 2007; 51: 325-331.
55. Sahin A, Kiratli H, Tezel GG et al. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas. Ophthalmic Research 2007; 39: 40-44.
56. Wolfesberger B, Guija de Arespacohaga A, Willmann M et al. Expression of vascular endothelial growth factor and its receptors in canine lymphoma. Journal of Comparative Pathology 2007; 137: 30-40.
57. Al-Dissi AN, Haines DM, Singh B et al. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas. Veterinary Pathology 2007; 44: 823-830.
58. Millanta F, Silvestri G, Vaselli C et al. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Research in Veterinary Science 2006; 81: 350-357.
59. Rebuzzi L, Willmann M, Sonneck K et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology 2007; 115: 320-333.
60. Kollermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. American Journal of Clinical Pathology 2001; 116: 115-121.
61. Takahashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research 1995; 55: 3964-3968.
62. Chi JT, Thrall DE, Jiang C et al. Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics. Clinical Cancer Research 2011; 17: 2549-2560.